The Inaugural UCLA Kidney-Liver Connection Symposium

We are planning the inaugural UCLA Kidney–Liver Disease Symposium, an interdisciplinary educational forum focused on the growing clinical intersection between hepatic and renal disorders. The strong bidirectional relationship between liver and kidney disease has long been recognized, most notably in hepatorenal syndrome—a devastating complication of decompensated cirrhosis associated with exceedingly high short- and intermediate-term mortality. Despite recent therapeutic advances, outcomes remain poor, underscoring the critical need for continued education to support healthcare professionals in evidence-based management. This symposium will convene experts in nephrology, hepatology, transplant nephrology, and interventional radiology to provide state-of-the-art perspectives on hepatorenal syndrome and other complex conditions affecting both organ systems, with the goal of enhancing clinical knowledge and improving patient outcomes.

Fees 

In-person & Virtual Attendance

• $100 Physicians

• $75 Allied Health Professionals

UC Recharge Payment Information
Registration payment can be submitted via the Interdepartmental or Intercampus recharge system.
For more details, please refer to document here: Recharge Information

Refunds
Cancellations must be received via email to [email protected] by Sunday, June 28, 2026 and will be subject to a $50 processing fee. No refunds will be granted after that date. David Geffen School of Medicine at UCLA reserves the right to cancel or postpone this course if necessary; in the event of cancellation, course fees will be fully refunded to the original form of payment. We are not responsible for other costs, such as non-refundable airline tickets or hotel penalties. 

Course Recording
The course will not be recorded.

1. Analyze the pathophysiology, epidemiology, classification, and prognostic implications of hepatorenal syndrome to support earlier recognition, risk stratification, and evidence-based diagnosis.
2. Evaluate evidence-based therapeutic strategies for hepatorenal syndrome–acute kidney injury (HRS-AKI), including vasoconstrictor therapy, albumin optimization, transjugular intrahepatic portosystemic shunt (TIPS), transplantation approaches, and supportive care, through review of clinical trial data, patient selection considerations, safety considerations, limitations of existing evidence, and practical application in routine care.
3. Compare current national and international guideline recommendations and evaluate areas of ongoing controversy and emerging evidence in hepatorenal syndrome management.
4. Recognize additional kidney–liver interactions, including metabolic dysfunction-associated steatotic liver disease (MASLD), hyponatremia in cirrhosis, and liver-associated glomerular disease, highlighting diagnostic and management challenges that require multidisciplinary care and individualized clinical decision-making.
5. Develop multidisciplinary care strategies across hepatology, nephrology, transplant medicine, critical care, and interventional radiology to improve coordination of care and consistency of evidence-based management.
6. Evaluate strategies to reduce delays in diagnosis and treatment of hepatorenal syndrome–acute kidney injury (HRS-AKI) with the goal of improving patient outcomes, including renal recovery, timely transplant evaluation, and survival.
7. Evaluate real-world clinical challenges in kidney–liver disease through multidisciplinary case-based discussion with faculty experts to identify strategies that support collaboration, innovation, and evidence-based patient care.

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The California State Board of Registered Nursing accepts courses approved by the AMA PRA Category 1 Credits™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies. 

Ronald Reagan UCLA Medical Center - Tamkin Auditorium (B-Level)

757 Westwood Plaza
Los Angeles, CA 90095

Parking and Directions
From the 405 freeway, exit Wilshire Blvd., East toward Westwood. Turn left on Westwood Blvd., travel past Charles E. Young Dr. South and turn left on “Structure 8 driveway”. Visitor parking is available in Lot 8 at a rate of $18 for the day. Please use the pay-by-plate stations to purchase your parking permit. The Ronald Reagan UCLA Medical Center is located on the corner of Westwood Plaza and Charles E. Young Dr. South.

Mitigation of Relevant Financial Relationships

The Accreditation Council for Continuing Medical Education (ACCME), Standards for Integrity and Independence mandates that the accreditation manages all identified relevant financial relationship(s) before the program and adequately discloses relationships to learners. The David Geffen School of Medicine at UCLA adheres to the ACCME Standards for Integrity and Independence in accredited continuing education.

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Daniel Chambers
UCLA

CCPD Staff

Nothing to disclose

Ericka Cunningham, MBA
UCLA David Geffen School of Medicine

CCPD Staff

Nothing to disclose

Charles Flippen II, MD, FAAN, FANA
David Geffen School of Medicine at UCLA

CCPD Staff

Nothing to disclose

Yunmi Kim
David Geffen School of Medicine at UCLA

CCPD Staff

Nothing to disclose

Je'Rel Smith, MA
CCPD

CCPD Staff

Nothing to disclose

Kimberly Valencia, CHCP
UCLA David Geffen School of Medicine

CCPD Staff

Nothing to disclose

Timofey Vints, other
UCLA Health

CCPD Staff

Nothing to disclose

Farid Arman, MD, FASN
Physician

Co-Director, Faculty

Advisor-AbbVie (Relationship has ended)|Consulting Fee-Travere (Relationship has ended)|Consulting Fee-Calitidas (Relationship has ended)|Speakers Bureau-Mallinckrodt Pharmaceuticals|Speakers Bureau-Natera

Mohammad Kamgar, MD
Physician

Co-Director, Faculty

Speakers Bureau-Otsuka America Pharmaceutical, Inc.|Speakers Bureau-Callidiatas (Relationship has ended)|Speakers Bureau-Travere Therapeutic (Relationship has ended)|Speakers Bureau-GSK (Relationship has ended)|Speakers Bureau-Aurinia (Relationship has ended)|Advisor-Vera Therapeutics (Relationship has ended)

Lama M Abdelnour, MD, Medical Director of the living donor kidney transplant program
Physician

Faculty

Nothing to disclose

Dale Abel, MD, PhD
Physician

Faculty

Advisor-Amgen, Inc.

Ramon A Durazo, MD
Physician

Faculty

Ramy Hanna, MD

Faculty

Brian H Horwich, MD
Physician

Faculty

Nothing to disclose

Sentia Iriana, MD
Physician

Faculty

Edward Lee, MD, PhD
Physician

Faculty

Erik Lum, MD
Physician

Faculty

Nothing to disclose

Mitra Nadim, MD

Faculty

Susanne B Nicholas, MD, MPH, PhD, Professor of Medicine
UCLA David Geffen School of Medicine

Faculty

Niloofar Nobakht, MD
Physician

Faculty

Speakers Bureau-Ardelyx|Advisor-Vertex Pharmaceuticals|Speakers Bureau-Caliditas |Advisor-Travere|Advisor-Vera Theraputic |Independent Contractor (included contracted research)-Caliditas|Independent Contractor (included contracted research)-Novartis Corporation Pharmaceuticals|Independent Contractor (included contracted research)-Aurinia (Relationship has ended)|Independent Contractor (included contracted research)-Vertex Pharmaceuticals (Relationship has ended)

Mrinalini Sarkar, MD
Physician

Faculty

Nothing to disclose

Jasleen Singh, MD, Assistant Professor of Medicine and Surgery
Physician

Faculty

Speakers Bureau-Madrigal Pharmaceuticals

Beshoy Yanny, MD

Faculty

Sammy Saab, MD, FAASLD, ACG, AGAF
Physician

Faculty, Other Planning Committee Member

Speakers Bureau-AbbVie (Any division)|Speakers Bureau-madrigal|Honoraria-Ipsen Biopharmaceuticals, Inc.|Speakers Bureau-novo nordisk|Speakers Bureau-Bausch (formerly Salix)|Speakers Bureau-Mallinckrodt Pharmaceuticals|Speakers Bureau-Eisai, Inc.|Speakers Bureau-Exelixis, Inc. (Relationship has ended)|Speakers Bureau-gilead (Relationship has ended)

Saturday, July 18, 2026

EXHIBITOR REGISTRATION

1) Complete the Exhibitor Letter of Agreement (LOA).
2) New Users: Click here to create account and profile set up.
3) Click here to make payment.